Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Hongzhen Fan

Datos Biográficos

ID7956557
NOMBREHongzhen Fan
NOMBRESHongzhen
APELLIDOFan
FIRMAFAN H
AFILIACIONESPeking University
ORCID0000-0001-9903-2210
VERIFICADOSí
TOTAL DE OBRAS6
TOTAL DE CITAS0
TOTAL COMO AUTOR6
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2021
AÑO MÁS RECIENTE DE PUBLICACIÓN2023
ÍNDICE H0
  • Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the Covid-19 pandemic

    Open Access•Botao Ma, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2023

    The results suggested that clinicians and pharmacists should adjust the CLO dose based on changes in smoking status in patients stabilized with CLO during the COVID-19 pandemic. Careful TDM for CLO should be performed prior to dose adjustment,to reduce the increased risk of smoking cessation induced side effects, especially for older patients receiving multiple medications

  • Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls

    Open Access•Song Chen, Mengzhuang Gou et al.•ARTICLE•Frontiers in Psychiatry•2022

    Innate immune components involved in host defense have been implicated in schizophrenia (SCZ). However, studies exploring their clinical utility in SCZ diagnosis are limited. The main purpose of this study was to evaluate whether circulating endotoxin, high mobility group box 1 protein (HMGB1) and complement component 4 (C4) could act as peripheral biomarkers to distinguish first-episode schizophrenia (FES, n = 42) patients from healthy controls …

  • Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia

    Open Access•Huimei An, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2022

    These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia

  • Vocal Acoustic Features as Potential Biomarkers for Identifying/Diagnosing Depression

    Open Access•Qing Zhao, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2022

    The acoustic expression of emotion among patients with depression differs from that of normal controls. Some acoustic characteristics are related to the severity of depressive symptoms and may be objective biomarkers of depression. A systematic method of assessing vocal acoustic characteristics could provide an accurate and discreet means of screening for depression; this method may be used instead of-or in conjunction with-traditional screening …

  • Subcortical Brain Volumes Relate to Neurocognition in First-Episode Schizophrenia, Bipolar Disorder, Major Depression Disorder, and Healthy Controls

    Open Access•Jing Shi, Hua Guo et al.•ARTICLE•Frontiers in Psychiatry•2022

    The different degrees of subcortical volume lessening may contribute to the differences in cognitive impairment among the three psychiatric disorders

  • High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia

    Open Access•Yongqian Wang, Xu-Feng Huang et al.•ARTICLE•Frontiers in Psychiatry•2021

    Background: There is currently no effective treatment for cognitive impairment associated with schizophrenia (CIAS). Recent studies have shown that increased histamine levels in the brain may help to improve CIAS symptoms. Betahistine is an H1-receptor agonist and H3-receptor antagonist. This study evaluated the effect of high-dose betahistine on cognitive function as well as its safety in Chinese Han patients with schizophrenia. Methods: This ra…

Sin obras prominentes en esta página.

  • High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia

    Open Access•Yongqian Wang, Xu-Feng Huang et al.•ARTICLE•Frontiers in Psychiatry•2021

    Background: There is currently no effective treatment for cognitive impairment associated with schizophrenia (CIAS). Recent studies have shown that increased histamine levels in the brain may help to improve CIAS symptoms. Betahistine is an H1-receptor agonist and H3-receptor antagonist. This study evaluated the effect of high-dose betahistine on cognitive function as well as its safety in Chinese Han patients with schizophrenia. Methods: This ra…

  • Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls

    Open Access•Song Chen, Mengzhuang Gou et al.•ARTICLE•Frontiers in Psychiatry•2022

    Innate immune components involved in host defense have been implicated in schizophrenia (SCZ). However, studies exploring their clinical utility in SCZ diagnosis are limited. The main purpose of this study was to evaluate whether circulating endotoxin, high mobility group box 1 protein (HMGB1) and complement component 4 (C4) could act as peripheral biomarkers to distinguish first-episode schizophrenia (FES, n = 42) patients from healthy controls …

  • Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia

    Open Access•Huimei An, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2022

    These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia

  • Vocal Acoustic Features as Potential Biomarkers for Identifying/Diagnosing Depression

    Open Access•Qing Zhao, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2022

    The acoustic expression of emotion among patients with depression differs from that of normal controls. Some acoustic characteristics are related to the severity of depressive symptoms and may be objective biomarkers of depression. A systematic method of assessing vocal acoustic characteristics could provide an accurate and discreet means of screening for depression; this method may be used instead of-or in conjunction with-traditional screening …

  • Subcortical Brain Volumes Relate to Neurocognition in First-Episode Schizophrenia, Bipolar Disorder, Major Depression Disorder, and Healthy Controls

    Open Access•Jing Shi, Hua Guo et al.•ARTICLE•Frontiers in Psychiatry•2022

    The different degrees of subcortical volume lessening may contribute to the differences in cognitive impairment among the three psychiatric disorders

  • Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the Covid-19 pandemic

    Open Access•Botao Ma, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2023

    The results suggested that clinicians and pharmacists should adjust the CLO dose based on changes in smoking status in patients stabilized with CLO during the COVID-19 pandemic. Careful TDM for CLO should be performed prior to dose adjustment,to reduce the increased risk of smoking cessation induced side effects, especially for older patients receiving multiple medications

Psychiatry (6 obras) · Internal Medicine (5 obras) · Medicine (5 obras) · Schizophrenia (object-oriented programming (5 obras) · Schizophrenia research and treatment (4 obras) · Psychology (3 obras) · Antipsychotic (2 obras) · Biomarker (2 obras) · Brief Psychiatric Rating Scale (2 obras) · Cognition (2 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae